Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
Article Date
November 11, 2025
This article is featured on another website.
Go to article
September 11, 2026
Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials
Part 4 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
September 11, 2026
Data Governance and Geopolitics: The New Operational Reality of Global Clinical Trials
Part 4 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…
July 10, 2026
Sarcoma Clinical Trials – Cell Therapy’s Solid-Tumor Breakthrough, and What It Means for a Rare Cancer
A Turning Point for Cell Therapy in Solid Tumors, and for Sarcoma For most of…